Cardiac progenitor cell therapy: mechanisms of action

Cell & Bioscience

Table 3 Clinical trials: the use of cardiac stem cells in cardiovascular disorders

NCT Number	Study name	Date	Phase	Patients	Cell source	Disease	Results	Ref.
NCT00893360	CADUCEUS	2009–2011	I	17	Autologous CDCs	ILVD	-increased viable of myocardium -decreased scar size -improved regional function of infarcted myocardium	[51]
NCT00474461	SCIPIO	2009–2013	I	33	Autologous CDCs	ICM	-reduction in infarct size -improving left ventricular function	[52]
NCT01273857	TICAP	2011–2013	I	14	Autologous CDCs	HLHS	-improvement of right ventricular ejection fraction	[53]
NCT01458405	ALLSTAR	2012–2019	I, II	134	Allogenic CDCs	ILVD	-not reduce scar size -decrease in left ventricular end-diastolic volume -decrease in left ventricular end-systolic volume	[54]
NCT01829750	PERSEUS	2013–2016	II	41	Autologous CDCs	HLHS	-reduced heart failure - favorable effect on ventricular function	[55, 56]
NCT02057900	ESCORT	2013–2018	I	6	CSCs	ILVD	-increased systolic motion of the cell-treated segments -patients with improved symptoms	[57]
NCT02439398	CAREMI	2014–2016	I, II	55	Allogenic CSCs	MI	-CSCs can be safely administered to patients after MI	[58, 59]
NCT02501811	CONCERT-HF	2015–2020	II	125	c-kit^POS cells and MSCs	IHD	-treatment is safe and feasible -the proportion of MACE was significantly decreased	[60]
NCT02485938	HOPE	2016–2017	I, II	25	Allogenic CDCs	CM - DMD	-decreased scar size -improvement of systolic thickening of the inferior wall	[61]
NCT03129568	TICAP-DCM	2017–2018	I	5	CDCs	DCM	-improved cardiac function	[62]

CDCs - Cardiosphere-Derived Stem Cells, CM - Cardiomyopathy, CSCs - Cardiac Stem Cells, DCM - Dilated Cardiomyopathy, DMD - Duchenne Muscular Dystrophy, HLHS - Hypoplastic Left Heart Syndrome, ICM - Ischemic Cardiomyopathy, IHD - Ischemic Heart Disease, ILVD - Ischemic Left Ventricular Dysfunction, MACE - Major Adverse Cardiac Events, MI - Myocardial Infarction, MSCs - Mesenchymal Stem Cells

ISSN: 2045-3701